Recursion Pharmaceuticals, Inc. (RXRX) NASDAQ
3.81
+0.2227(+6.20%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
3.81
+0.2227(+6.20%)
Currency In USD
| Previous Close | 3.59 |
| Open | 3.52 |
| Day High | 3.84 |
| Day Low | 3.45 |
| 52-Week High | 7.18 |
| 52-Week Low | 2.77 |
| Volume | 24.02M |
| Average Volume | 13.99M |
| Market Cap | 1.71B |
| PE | -3.29 |
| EPS | -1.16 |
| Moving Average 50 Days | 3.28 |
| Moving Average 200 Days | 4.27 |
| Change | 0.22 |
Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes’ Lightning Talk at the NVIDIA GTC AI Co
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
GlobeNewswire Inc.
Feb 18, 2026 1:30 PM GMT
Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMTSalt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically im
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
GlobeNewswire Inc.
Feb 12, 2026 12:59 PM GMT
Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Bo